ZYMOSAN A
ZYMOSAN A Basic information
- Product Name:
- ZYMOSAN A
- Synonyms:
-
- Zymosan A from Saccharomyces cerevisiae Vetec(TM) reagent grade
- ZYMOSAN
- ZYMOSAN A
- anticomplementary factor
- Zymosan A fromSaccharomycecerevisiae
- zymosan A from saccharomyces cerevisiae
- Zymosan A from saccharomyees cerevisiae
- YEAST POLYSACCHARIDES
- CAS:
- 58856-93-2
- MF:
- n.a.
- MW:
- 0
- EINECS:
- 232-725-5
- Mol File:
- Mol File
ZYMOSAN A Chemical Properties
- RTECS
- ZI2750000
- storage temp.
- 2-8°C
- solubility
- Chloroform: 100 μg/ml; DMSO: 200 μg/ml; Ethanol: 100 μg/ml
- form
- Powder
- color
- off-white to light brown
- biological source
- Saccharomyces cerevisiae
Safety Information
- Hazard Codes
- Xi
- Risk Statements
- 36/37/38
- Safety Statements
- 22-24/25-36-26
- WGK Germany
- 3
- F
- 10
- HS Code
- 3913900099
MSDS
- Language:English Provider:SigmaAldrich
ZYMOSAN A Usage And Synthesis
Uses
Zymosan A from Saccharomyces cerevisiae has been used:
- as a positive control to determine the activation of complement cascade
- for respiratory burst (RB) assay
- to assess its effects on performance, immunity, heat shock protein and apoptosis related gene expressions of dairy cows under heat stress (HS)
- a stimulating agent in Krebs-Ringer phosphate (KRP) medium
- to induce thermal hyperalgesia in mice
Biochem/physiol Actions
Zymosan is prepared from yeast cell wall and consists of protein-carbohydrate complexes. It is used to induce experimental sterile inflammation. In macrophages, zymosan-induced responses include the induction of proinflammatory cytokines, arachidonate mobilization, protein phosphorylation, and inositol phosphate formation. Zymosan A also raises cyclin D2 levels suggesting a role for the latter in macrophage activation besides proliferation. It potentiates acute liver damage after galactosamine injection suggesting that certain types of nonparenchymal cells other than Kupffer cells are involved in zymosan action. Zymosan A, a 13 beta glucan contributes to the development of organic dust-induced respiratory disease.
in vivo
Zymosan A (25.0?mg/kg; IP at 12 and 2?h before IR) mitigates IR-induced intestinal injury in mice[1]. Zymosan A can be used in animal modeling to create peritonitis models.
Administration: 100 or 500 mg/kg ? i.p.
(2) Preparation of Zymosan A Suspension: Weigh Zymosan A and sterilise for 30 minutes with UV light, add sterile filtered saline and vortex thoroughly, store at room temperature overnight and vortex again before use to ensure thorough mixing.
(3) Rectal temperature and ECG were recorded hourly 4 and 24 hours after Zymosan A injection, respectively.
| Animal Model: | 20.0?Gy abdominal irradiation (ABI) model in mice[1] |
| Dosage: | 25.0?mg/kg, dissolved in NS |
| Administration: | IP; injection at 12 and 2?h before IR |
| Result: | Significantly reduced the degree of bleeding and edema in the intestinal tissue. |
ZYMOSAN ASupplier
- Tel
- 400-1166-196 18981987031
- cdhxsj@163.com
- Tel
- 0731-85526065 13308475853
- ivy@hnhbsj.com
- Tel
- 021-021-021-67601398-809-809-809 15221380277
- marketing_china@spectrumchemical.com
- Tel
- 0411-62910999 13889544652
- sales@meilune.com
- Tel
- 021-61312847 13636370518
- shyysw007@163.com
ZYMOSAN A(58856-93-2)Related Product Information
- TRIS(2,2,6,6-TETRAMETHYL-3,5-HEPTANEDIONATO)DYSPROSIUM(III)
- TERT-BUTYL ISOCYANIDE
- N-BUTYLISOCYANIDE
- TRIS(2,2,6,6-TETRAMETHYL-3,5-HEPTANEDIONATO)EUROPIUM(III)
- Benzyl isocyanide
- Tosylmethyl isocyanide
- DICHLORO(ETHYLENEDIAMINE)PLATINUM(II)
- METHYL ISOCYANOACETATE
- Tris(2,4-pentanedionato)chroMiuM(III)
- Ferric acetylacetonate
- SALCOMINE
- Cupric acetylacetonate
- Ethyl isocyanoacetate
- Aluminum acetylacetonate
- COBALT(II) ACETYLACETONATE
- 2,4-PENTANEDIONE, SILVER DERIVATIVE
- 1,1,3,3-TETRAMETHYLBUTYL ISOCYANIDE
- ZYMOSAN A OPSONIZING REAGENT,ZYMOSAN A (S CEREVISIAE),BIOPARTICLE OPSONIZING REAGENTS FOR S CEREVISIAE (ZYMOSAN)